ProKidney Corp. (PROK)
NCM · Healthcare · Biotechnology
Closing price as of 2026-07-30 · Source: TEK2day Finance
Key Metrics
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 221K | 217K | 225K | 226K |
| Operating Income | -39.7M | -38.5M | -45.4M | -44.9M |
| Net Income | -16.6M | -16.5M | -19.2M | -20.0M |
| Diluted EPS | $-0.13 | $-0.12 | $nan | $-0.14 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 76K | 893K |
| Operating Income | -153.0M | -151.5M | -183.7M | -165.0M |
| Net Income | -108.0M | -35.5M | -61.2M | -69.0M |
| Diluted EPS | $-0.23 | $-0.57 | $-0.62 | $-0.52 |